Table 2.
Treatment characteristics of the cohort.
| Treatment characteristic | No. of patients (%) |
|---|---|
|
| |
| Initial treatment (N=153) | |
| PDS | 89 (58) |
| IDS | 50 (33) |
| No surgery, chemotherapy alone | 14 (9) |
| Reason for neoadjuvant chemotherapy (N=50) | |
| Extent of disease | 37 (74) |
| Pulmonary embolism at diagnosis | 6 (12) |
| Poor performance status | 6 (12) |
| Synchronous diagnosis of ovarian and breast cancers | 1 (2) |
| Complete gross resection (CGR) (N=139) | |
| CGR for PDS (n=89) | 68 (76.4) |
| CGR for IDS (n=50) | 33 (66) |
| Residual disease (RD) (N=38) | |
| 1–10 mm RD after PDS | 18 (47.4) |
| 1–10 mm RD after IDS | 10 (26.3) |
| >10 mm RD after PDS | 3 (7.9) |
| >10 mm RD after IDS | 7 (18.4) |
| Time from surgery to chemotherapy | |
| Median time (range), days | 36 (15–87) |
| Intraperitoneal chemotherapy (N=153) | |
| Yes | 55 (36) |
| No | 95 (62.1) |
| Unknown | 3 (1.9) |
| Bevacizumab maintenance, 1st line (N=153) | |
| Yes | 5 (3.3) |
| No | 145 (94.8) |
| Unknown | 3 (1.9) |
| Investigational agent: PARPi/placebo, 1st line (N=153) | |
| Yes | 5 (3.3) |
| No | 145 (94.8) |
| Unknown | 3 (1.9) |
| First recurrence/POD (N=111 * ) | |
| Chemotherapy alone (n=110) | 80 (72.7) |
| No treatment (n=110) | 2 (1.8) |
| Secondary cytoreductive surgery (n=110) | 28 (25.5) |
| CGR (n=28) | 25 (89.3) |
| Any RD (n=28) | 3 (10.7) |
| Bevacizumab maintenance, 2nd line (N= 110) | |
| Yes | 22 (20) |
| No | 86 (78.2) |
| Unknown | 2 (1.8) |
| PARPi maintenance, 2nd line (N=110) | |
| Yes | 23 (20.9) |
| No | 85 (77.3) |
| Unknown | 2 (1.8) |
| Second recurrence/POD (N=84 ^ ) | |
| Chemotherapy alone | 77 (93.9) |
| Declined treatment | 1 (1.2) |
| Tertiary cytoreductive surgery | 4 (4.9) |
| CGR (n=4) | 4 (100) |
| Treatment lines (N=153) | |
| 0 | 1 (0.7) |
| 1 | 42 (27.5) |
| 2 | 26 (17.0) |
| 3 | 28 (18.3) |
| 4 | 15 (9.8) |
| 5 | 10 (6.5) |
| 6 | 14 (9.2) |
| 7 | 9 (5.9) |
| 8 | 3 (2.0) |
| 9 | 1 (0.7) |
| Unknown | 4 (2.6) |
| Palliative surgery for malignant bowel obstruction | 7 (4.6) |
*
One patient lost to follow-up
^
Two patients lost to follow-up
PDS, primary debulking surgery; IDS, internal debulking surgery; PARPi, poly ADP-ribose polymerase inhibitor; POD, progression of disease